Publication | Closed Access
\documentclass{article}\pagestyle{empty}\begin{document}$ \left[\!\left[ {} \right.\right. $ \end{document}[(Dialkylamino)alkyl]amino\documentclass{article}\pagestyle{empty}\begin{document}$ \left.\left. {} \right]\!\right] $ \end{document}pyrimido[1,2‐<i>a</i>]benzimidazoles,2,3‐dihydro‐1<i>H</i>‐cyclopenta[4,5]pyrimido[1,2‐<i>a</i>]benzimidazoles, and <i>s</i>‐triazolo[1,5‐<i>a</i>]pyrimidines as potential antimalarial agents
28
Citations
18
References
1969
Year
Molecular PharmacologyMedicinal ChemistryNmr SpectroscopyAntiparasitic AgentNatural SciencesDrug DiscoveryDiversity-oriented SynthesisPotential Antimalarial AgentsMedicineOrganic ChemistryEthyl Aceto‐acetateR OhChemistryHeterocycle ChemistryPharmacologyPharmaceutical ChemistrySynthetic ChemistryBiomolecular Engineering
Abstract The structure of the product of the reaction of 2‐aminobenzimidazole with ethyl aceto‐acetate has been established by NMR spectroscopy as 2‐melhylpyrimido[1,2‐ a ]benzimidazol‐4‐ol (III). 7(and 8)‐Chloro‐2‐methylpyrimido[l,2‐ a ]benzimidazol‐4‐ol (VI and VIII, R OH), 2‐(trifluoromethyl)pyrimido[i,2‐ a ]benzimidazol‐4‐ol (X), 2,7,8‐trimethylpyrimido[1,2‐ a ]benzimidazol‐4‐ol (XII), 2‐benzyl‐1,2,3,4‐tetrahydropyrido[4′,3′:4,5]pyrimido[1,2‐ a ]benzimidazol‐12‐ol (XIII), 1,2,3,4‐tetrahydrobenzimidazo[2,1‐ b ]quinazolin‐12‐ol (XIV), and 2,3‐dihydro‐1 H ‐cyclopenta[4,5]pyrimido[1,2‐ a ]benzimidazol‐11‐ol (XV) were prepared in a similar manner. Chlorination of III, VI and VIII, XV, and 5‐methyl‐ s ‐triazolo[1,5‐ a ]pyrimidin‐7‐ol (XXV, R OH) with phosphorus oxychloride afforded the corresponding chloroheterocycles, which were condensed with the appropriate N,N ‐dialkylalkylenediamine or Nα,Nα ‐diethyl‐6‐methoxytoluene‐α,3‐diamine to give various 4‐ \documentclass{article}\pagestyle{empty}\begin{document}$ \left[\!\left[ {} \right.\right. $ \end{document} [(dialkylamino)alkyl]amino \documentclass{article}\pagestyle{empty}\begin{document}$ \left[\!\left[ {} \right.\right. $ \end{document} ‐2‐methylpyrimido[1,2‐ a ]benzimidazoles (Va‐e, VII, IX), 11‐ \documentclass{article}\pagestyle{empty}\begin{document}$ \left.\left. {} \right]\!\right] $ \end{document} [(dialkylamino)alkyl]amino \documentclass{article}\pagestyle{empty}\begin{document}$ \left[\!\left[ {} \right.\right. $ \end{document} ‐2,3‐dihydro‐1 H ‐cyclopenta[4,5]‐pyrimido[1,2‐ a ]benzimidazoles (XVIa and b), and 7‐ \documentclass{article}\pagestyle{empty}\begin{document}$ \left[\!\left[ {} \right.\right. $ \end{document} [(dialkylamino)alkyl]amino \documentclass{article}\pagestyle{empty}\begin{document}$ \left.\left. {} \right]\!\right] $ \end{document} ‐5‐methyl‐ s ‐triazolo[1,5‐ a ]pyrimidines (XXVb‐e). None of these compounds displayed significant antimalarial activity against Plasmodium berghei in the mouse.
| Year | Citations | |
|---|---|---|
Page 1
Page 1